Bifosfonatos en osteoporosis: actualización

1. Fleish H. Bisphosphonates in bone diseases. From the laboratory to the patient.

Third Edition. The Parthenon Publishing Group Inc. London, 1997

2. Kanis JA. Drugs used for the treatment of Paget´s disease of bone. London:

Martin Dunnitz,1991:139-216.

3. O´Doherty DP, Bickerstaff DR, McCloskey EV, et al. Treatment of Paget´s disease of bone with aminohydroxybutylidene-1bisphosphonate. J Bone Min

Res 1990:5, 483-491.

4. Adami S, Salvagno, Guarrera G, et al. Treatment of Paget´s disease of bone with intravenous 4 amino-1hydroxybutylidene-1,1bisphosphonates. Calcif

Tissue Int 1986;39:226-229.

5. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget´s disease of bone. J Clin Endocrinol Metabol 1996;81 (3):961-967.

6. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical ad radiologic improvement in Paget´s disease of bone treated with alendronate. A randomized, placebo-controlled trial. Am J Med 1996;101:341-348.

7. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget´s disease of bone. Bone 1994;15:415-417.

8. Miller PD, Brown S